Thesis
CNM-Au8 pursues accelerated ALS approval on NfL biomarker data; FDA's acceptance of surrogate endpoint at NDA review is the decisive test
CNM-Au8 is a nanocrystalline gold suspension targeting neurodegeneration in ALS patients with demonstrated NfL and survival biomarker signals from the HEALEY platform trial and NIH-sponsored expanded access program. The thesis turns on whether FDA accepts NfL reduction as a reasonably likely surrogate endpoint sufficient to grant accelerated approval under Subpart H, converting biomarker data into a conditional approval without a completed Phase 3. The primary risks are FDA declining to accept the surrogate at NDA filing review and the structural precedent that no prior ALS drug has achieved accelerated approval via a fluid biomarker surrogate, with riluzole and edaravone having required functional or survival endpoints.
Focus
NDA filing for CNM-Au8 in ALS
Q3 2026
Bull
A successful NDA submission accepted for review by FDA would validate the accelerated approval pathway strategy and trigger the $6.7M Series A Warrant tranche, extending the financial runway while signaling that FDA finds the NfL biomarker package sufficient to proceed; this would represent a de-risking inflection point that materially re-rates the stock ahead of a PDUFA decision.
Bear
FDA could refuse to file or issue a refuse-to-file letter on the grounds that the NfL magnitude data do not adequately establish a link between biomarker reduction and clinical benefit, which is the explicit condition FDA attached in the Type C meeting; alternatively, the $7M capital raise may prove insufficient to complete the NDA package to FDA's standard, delaying submission beyond 2026 and further pressuring the balance sheet.
Unlock the full thesis for CLNN.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.